ABT-333 is a nonnucleoside NS5B polymerase inhibitor for the treatment of HCV infection. An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot study involving patients with HCV genotype 1 infection. ABT-333 is currently under clinical trials for the treatment of Hepatitis C.

>98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

Dasabuvir

DMSO ≥46 mg/mL

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
Kowdley KV,et al. N Engl J Med. 2014 Jan 16;370(3):222-32. PMID: 24428468.
䔸Żᩄ族痛셌Ų族痛셌ŲItem褐Count๏
﯈趌๐侮᠜׶靴๟
ᠠ׶iS￿￿ññ眘⮦眀⮦敲痛๏
ࠃ馸๟鳘๟௼଩祖ItemCount3᬴叫㺍痭ᠠ׶靴๟i縉靴๟蘿敌ଧ靴๟ᠠ׶i᭰叫㺍痭ᡸ׶顴